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Abdulrahman N, Jaspard-Vinassa B, Fliegel L, Jabeen A, Riaz S,
Gadeau AP, Mraiche F. Na/H exchanger isoform 1-induced osteo-
pontin expression facilitates cardiac hypertrophy through p90 ribosomal
S6 kinase. Physiol Genomics 50: 332–342, 2018. First published Febru-
ary 23, 2018; doi:10.1152/physiolgenomics.00133.2017.—Cardiovascu-
lar diseases are the leading cause of death worldwide. One in three cases
of heart failure is due to dilated cardiomyopathy. The Na/H exchanger
isoform 1 (NHE1), a multifunctional protein and the key pH regulator in
the heart, has been demonstrated to be increased in this condition. We
have previously demonstrated that elevated NHE1 activity induced car-
diac hypertrophy in vivo. Furthermore, the overexpression of active
NHE1 elicited modulation of gene expression in cardiomyocytes includ-
ing an upregulation of myocardial osteopontin (OPN) expression. To
determine the role of OPN in inducing NHE1-mediated cardiomyocyte
hypertrophy, double transgenic mice expressing active NHE1 and OPN
knockout were generated and assessed by echocardiography and the
cardiac phenotype. Our studies showed that hearts expressing active
NHE1 exhibited cardiac remodeling indicated by increased systolic and
diastolic left ventricular internal diameter and increased ventricular
volume. Moreover, these hearts demonstrated impaired function with
decreased fractional shortening and ejection fraction. Atrial natriuretic
peptide (ANP) and brain natriuretic peptide (BNP) mRNA was
upregulated, and there was an increase in heart cell cross-sectional
area confirming the cardiac hypertrophic effect. Moreover, NHE1
transgenic mice also showed increased collagen deposition, upregu-
lation of CD44 and phosphorylation of p90 ribosomal s6 kinase
(RSK), effects that were regressed in OPN knockout mice. In conclu-
sion, we developed an interesting comparative model of active NHE1
transgenic mouse lines which express a dilated hypertrophic pheno-
type expressing CD44 and phosphorylated RSK, effects which were
regressed in absence of OPN.
cardiac hypertrophy; Na/H exchanger isoform 1; osteopontin; p90
ribosomal s6 kinase
INTRODUCTION
Cardiovascular diseases (CVD) are the leading cause of
death globally with an expectation of more than 23.6 million
deaths per year by 2030. Mortality due to CVD represented
31% of all global deaths in the year 2013 (42). Cardiac
hypertrophy is a type of cardiac remodeling characterized by
enlargement of heart and individual myocytes. Cardiac hyper-
trophy is either due to physiological (pregnancy, exercise) or
pathological (hypertension, ischemia) conditions. Cardiac hy-
pertrophy is a compensatory mechanism by the heart to adapt
with the hemodynamic load exerted and, if prolonged, may
result in heart failure (15, 26, 33).
Na/H Exchanger Isoform 1 Induces Cardiac Hypertrophy
Na/H exchangers are membrane proteins that function to
regulate intracellular pH by extruding intracellular H in
exchange of one extracellular Na (6, 24). Previous studies
have reported that enhanced activity of Na/H exchanger
isoform 1 (NHE1), a cardiac-specific form of Na/H ex-
changer family, promotes cardiac hypertrophy (44). Further-
more, inhibition of Na/H exchanger activity attenuated the
characteristics of isoproterenol induced cardiac hypertrophy in
rats (5). Moreover, NHE1 inhibition resulted in glycogen
synthase 3- activation and respective attenuation of hypertro-
phy in neonatal cardiomyocytes (12). A recent study has
reported that specific silencing of myocardial NHE1 with short
hairpin RNA is a therapeutic strategy to reduce cardiac hyper-
trophy (25). Another recent study has demonstrated that an
inhibitor of renal sodium glucose transporter (SGLT) 2, em-
pagliflozin, has an effect on regulating intracellular ion homeo-
stasis in cardiomyocytes through direct interaction with
Na/H exchanger without the involvement of SGLTs (1).
Unfortunately, the positive results seen in animal model were
not accomplished in clinical trials, where the administration of
a NHE1 inhibitor produced serious cerebrovascular side-ef-
fects in patients with coronary heart disease (13). Therefore,
exploring the signaling pathways downstream of NHE1 pro-
moting cardiac hypertrophy would be highly desirable, result-
ing in an indirect inhibition of NHE1 and thereby evading the
undesired side-effects of NHE1 inhibitors.
Osteopontin Mediates NHE1-induced Cardiac Hypertrophy
It was reported that activated NHE1 protein resulted in an
increased activation of osteopontin (OPN) (44), a multifunc-
tional protein that acts as a mediator in various cardiovascular
diseases (41) and whose expression is found to be increased in
conditions that promote cardiac hypertrophy (10, 43). Further-
more, an increase in OPN expression is seen in a Type 2
diabetes mellitus embryopathy model inducing cardiac fibrosis
and hypertrophy (16). Moreover, serum- and glucocorticoid-
inducible kinase (sgk1)-mediated cardiac hypertrophy and el-
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evated NHE1 expression induced by dexamethasone are ac-
companied by increased OPN expression (40). Furthermore, it
was demonstrated that NHE1-induced cardiac hypertrophy is
mediated by OPN through the calcineurin/nuclear factor of
activated T cell (NFAT) pathway (22). This infers that OPN is
a regulator in NHE1-induced cardiac hypertrophy, and OPN
will be a therapeutic target to cardiac hypertrophy. Therefore,
experiments were performed on transgenic mice overexpress-
ing NHE1 and OPN knockout overexpressing NHE1 mice to
delineate signaling mechanisms by which NHE1 induces OPN
expression and thereby contributes to cardiac hypertrophy.
p90 Ribosomal s6 Kinase as a Link between NHE1
and OPN?
Members of mitogen-activated protein kinase (MAPK) path-
way including extracellular signal regulated kinase (ERK) and
its downstream effectors have been implicated to play signif-
icant functions in pathogenesis of cardiac hypertrophy and
heart failure (37). Previous research has demonstrated that the
ERK pathway of the MAPK cascade activates NHE1 in re-
sponse to growth factors (2). Moreover, foregoing studies have
established that p90 ribosomal s6 kinase (RSK), a downstream
mediator of ERK, is a mediator of Na/H exchange activity
(34, 36).
Therefore, we hypothesize that NHE1-induced cardiac hy-
pertrophy mediated by OPN involves the activation of RSK.
To support our hypothesis, characteristics and biomarkers of
cardiac hypertrophy, activation of RSK, were analyzed and
compared in wild-type (WT) mice, NHE1 overexpressing
transgenic mice, OPN knockout NHE1 transgenic mice, and in
OPN knockout mice. We found that overexpression of NHE1
induced cardiac hypertrophy manifested by increased ANP and
BNP mRNA expression, increased heart cell cross-sectional
area, and increased collagen deposition. The collagen deposi-
tion was significantly reduced when OPN was knocked out
emphasizing the role of OPN in NHE1-induced cardiac hyper-
trophy. NHE1 overexpression also increased phosphorylation
of RSK, which was regressed in the absence of OPN.
MATERIALS AND METHODS
Materials
All routine chemicals were purchased from BD Biosciences (San
Jose, CA), Fisher Scientific (Ottawa, ON, Canada), or Sigma (St.
Louis, MO). Primary antibodies used for Western blotting included
rabbit antibody connexin 43 (c6219, Sigma), rabbit antibody NFAT
c4 (13036, Santa Cruz), rabbit antibody phospho-ERK 1/2 (9101, Cell
Signaling), rabbit antibody ERK 1/2 (9102, Cell Signaling), rabbit
antibody phospho p90RSK (9341, Cell Signaling), goat antibody
RSK2 (1430, Santa Cruz), rabbit antibody -tubulin (4074, Abcam),
and mouse antibody -tubulin (T5168, Sigma). Secondary antibodies
were purchased from Jackson laboratories and Abcam.
Mice
NHE1-overexpressing FVB mice were produced by CNRS, SEAT/
UPS 44, Villejuif, France. They were generated by transgenesis of a
plasmid overexpressing specifically in cardiac muscle cells, a hemag-
glutinin (HA)-tagged human NHE1, rendered constitutively active by
a mutation of the binding domain of calmodulin that normally causes
auto inhibition of NHE1 (11). Mice genotyping was performed by
standard PCR followed by agarose gel electrophoresis with primers
(forward: GAGACCGAGCAGGAGCTCGAG) and (reverse: CAG-
GTCCACAGACTCGGGTG), for characterizing NHE1 mutant.
OPN-deficient mice (OPN/) were obtained from Suzan Rittling
(Forsyth Institute, Harvard Medical School) and transferred to FVB
background. Mice genotyping was performed as previously described
using primers (AATATGCGAAGTGGACCTGG) and (GATCA-
AGCCATAGCCCTTCA) to characterize OPN interruption, and
primers (TCCAATGAAAGCCATGACC) and (GAAGAGTGAGT-
GAATCTGC) to detect WT OPN (29). We produced FVB double
transgenic mice expressing mutated NHE1 in OPN/ and verified
genotype by PCR with primers described above.
Mice were handled in the animal facility of INSERM U1034 in
accordance with the guidelines established by French Ministry of
Agriculture and complying with European Union regulations (license
no. B33-318-701). Blinding was achieved by use of a numbering
system, whereby each mouse was assigned a specific number, which
was not revealed to the individual analyzing the data. The protocol of
this project was approved under no. 5012018A by the local Animal
Care and Use Committee of Direction Départementale de la Protec-
tion des Populations. The Institutional Animal Care and Use Com-
mittee at Qatar University, Doha, Qatar, specifically approved this
project (Research Ethics Approval Number: QU-IACUC 007/2012).
Western Blot Analysis
Heart tissues were lysed in ice-cold RIPA buffer along with
protease inhibitors. Sonication (Branson SLPe) for a few seconds at
20% amplitude facilitated the lysis. Tissue lysates were centrifuged at
12,000 rpm for 15 min at 4°C. The supernatant containing protein was
collected and assayed with Bio-Rad DC protein assay kit to determine
the concentration. Protein samples (30–40 g) were denatured by
heating at 95°C for 5 min in Laemmli buffer. The samples were then
loaded on to SDS polyacrylamide gels. After the run, separated
protein samples were transferred on to a nitrocellulose membrane. The
membranes were incubated with 5% (wt/vol) nonfat milk or bovine
serum albumin, in Tris buffer saline, pH 7.4, with 0.1% Tween 20 for
at least 1 h at room temperature. Following the blocking stage, the
membranes were incubated overnight at 4°C with primary antibodies,
namely, anti-connexin 43, anti-NFAT, anti-pERK, anti-ERK, anti-
pRSK, and anti-RSK2. -Tubulin served as a loading control. The
membranes were then incubated with horseradish peroxidase-conju-
gated secondary antibodies at room temperature for 1 h and 30 min.
Visualization of bands was based on enhanced chemiluminescence
reaction. Imaging was done by Fluorchem M FM0564 imager and
quantification of bands was performed with Scion software.
Reverse Transcription Quantitative PCR
RNAs were isolated by using Tri Reagent (Molecular Research
Center), from cardiac muscle that had been snap-frozen in liquid
nitrogen and homogenized, as instructed by the manufacturer. For
quantitative RT-PCR analysis, total RNA was reverse transcribed with
M-MLV reverse transcriptase (Promega) and amplification was per-
formed on a DNA Engine Opticon2 (MJ Research) using B-R SYBER
Green SuperMix (Quanta Biosciences). The primers used are shown
in Table 1. The relative expression of each mRNA was calculated by
the comparative threshold cycle method and normalized to -actin
mRNA expression.
Histology and Immunohistochemistry
The mouse hearts were fixed in methanol and embedded in paraffin.
Paraffin blocks were sectioned in to 7 m sections and dried over-
night. The sections were then deparaffinized with xylene and rehy-
drated, after xylene removal, with alcohol.
Masson’s trichrome staining. Sections were dipped successively 1)
30 s in hematoxylin and washed 5 min in water, 2) 1 min in acidic
fuchsin and washed twice for 2 min in acetified water, 3) 5 min in
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phosphomolybdic acid and washed quickly in acetified water, 4) 2 min
in light green stain and washed twice quickly in acetified water.
Finally, sections were dehydrated by rapid bath in ethanol and xylene
and covered by coverslip with a xylene containing mounting resin.
Picrosirius red staining. Sections were incubated for 1 h in Sirius
red solution (1 g Sirius red F3B, Sigma-Aldrich) in 1 l of saturated
aqueous solution of picric acid) and then washed twice with acidified
water (0.5% acetic acid). Sections were than dehydrated by rapid bath
in ethanol and in xylene and covered by coverslip with a xylene
containing mounting resin. Observation was done with bright-field
microscope (Nikon). Collagen appeared in red on a pale yellow
background. Quantitative analysis was performed with Image J soft-
ware.
Wheat germ hemagglutinin. Wheat germ hemagglutinin (WGA)
binds on interstitial matrix. Sections were incubated 1 h in the dark
with lectin from triticum vulgaris FITC conjugate (# L4895; Sigma-
Aldrich, St. Louis, MO) diluted 1:100 (10 g/ml) in the required
buffer. After three washing steps, the sections were covered by
coverslip with a water-soluble antifading mounting medium contain-
ing DAPI. Observation was done with fluorescent microscope (Zeiss).
FITC appeared in green, and DAPI stained nuclei blue. Axiovision
was used for cell area measurement.
Immunohistology. The antigens were retrieved with Ventana CC1
buffer (Tris/EDTA buffer, pH 8) by treating the sections for 4 min at
95°C and then for 12 min at 100°C. The endogenous peroxidase was
quenched with 3% H2O2 in PBS for 30 min. Heart sections were then
blocked with Ab Diluent (ROCHE) for at least 20–30 min in a moist
chamber. The sections were then probed with primary antibodies to
HA tag, connexin 43 and CD44, in Ab Diluent (ROCHE) for 1 h at
37°C. Biotinylated anti-rabbit IgG secondary antibody (RPN1004V,
GE Healthcare) was then added at a dilution of 1:100 in Ab diluent
(ROCHE) for 1 h at 37°C. Finally, the 3,3-diaminobenzidine (DAB)
kit was used. The nuclei were counterstained with hematoxylin.
Images were acquired on NIKON microphot-FXA.
Transthoracic Echocardiography
Mice were lightly anesthetized with 1.5% isoflurane. Echocardiog-
raphy was performed with Vevo 2100 high-frequency high-resolution
ultrasound system (Fujifilm VisualSonics) to measure the lengths of
interventricular septum in systole (IVSs), interventricular septum in
diastole (IVSd), left ventricular internal diameter in systole (LVIDs),
left ventricular internal diameter in diastole (LVIDd), left ventricular
posterior wall in systole (LVPWs), left ventricular posterior wall in
diastole (LVPWd), ejection fraction (EF), fractional shortening (FS),
and volumes of left ventricle in systole (LVs) and in diastole (LVd).
The percentage of left ventricular (LV) fractional shortening (% FS)
was defined as % FS  [(LVIDd  LVIDs) / LVIDd] * 100.
Statistical Analysis
All values expressed were compared with control  SE. Student’s
t-test was used to compute differences between groups where a P 	
0.05 was considered a significant difference. Bonferroni correction
was utilized for analyzing multiple samples wherever applicable.
RESULTS
Characteristics of NHE1 Transgenic Mice
To determine the expression of NHE1 mRNA and protein in
NHE1 transgenic mice, quantitative PCR, immunohistochem-
ical analysis, and Western blot techniques were used. Figure
1A shows an increase in the ratio of endogenous NHE1 mRNA
expression to -actin, when compared with the WT (0.0122 
0.0008 WT vs. 0.0137  0.001 NHE1). However, this increase
was not significant, whereas the ratio of mutated or exogenous
NHE1 mRNA expression to -actin was significantly increased
when compared with the WT (0.85  0.3 NHE1; P  0.02)
(Fig. 1B). Protein expression of NHE1 was also confirmed by
Western blot and immunostaining, where anti-hemagglutinin
(HA) tag binds to the HA portion of NHE1 protein (Fig. 1, C
and D).
Table 1. List of primers used in quantitative PCR
NHE1
forward GCCATTGAGCTGGTGGAGAG
reverse CGGTCTGAAGTCACAGCCTTG
Endogenous NHE1
forward GGGGATTTCATCCACCTCGG
reverse GGGGATCACATGGAAACCTATCT
TIMP4
forward TGACACTCAAAAACTGATCCGGTA
reverse CATAGCAAGTGGTGATTTGGCAG
CTGF
forward GACCCAACTATGATGCGAGCC
reverse TCCCACAGGTCTTAGAACAGG
Integrin-3
forward GGAAGCAGCGCCCAGATCAC
reverse TTGTCCACGAAGGCCCCAAA
Collagen3A
forward CCATTTGGAGAATGTTGTGCAAT
reverse GGACATGATTCACAGATTCCAGG
Collagen1
forward CCCCGGGACTCCTGGACTT
reverse GCTCCGACACGCCCTCTCTC
MMP2
forward TTCGCTCGTTTCCTTCAACC
reverse ACTGGGCATGATCTGCACAG
PPAR
forward GGGTGGTTGAATCGTGAGG
reverse TGCCTTTTGCCAACAGTAGTAC
PGC1
forward AGACGGATTGCCCTCATTTGA
reverse TGTAGCTGAGCTGAGTGTTGG
SGK1
forward CTGCTCGAAGCACCCTTACC
reverse TCCTGAGGATGGGACATTTTCA
IL-6
forward CACTTCACAAGTCGGAGGCT
reverse CTGCAAGTGCATCATCGTTGT
OPN
forward TCCTATAGCCACATGGCTGG
reverse CAGAATCCTCGCTCTCTGCA
ANP
forward CGTCTTGGCCTTTTGGCTTC
reverse GGTGGTCTAGCAGGTTCTTGAAA
BNP
forward AAGCTGCTGGAGCTGATAAGA
reverse GTTACAGCCCAAACGACTGAC
CD44
forward TGGTGGCACACAGCTTGGGG
reverse GTCAGCTGCCTCAGTCCGGG
-Actin
forward CCTGAACCCTAAGGCCAACC
reverse TAGCCCTCGTAGATGGGCAC
cFOS
forward CAGCTCCCACCAGTGTCTAC
reverse TCTGCGCAAAAGTCCTGTGT
CREB
forward vACCCCTCCCCAAGCTAGTAT
reverse GGGCATGCACACGTCTTAAC
STAT3
forward TGCTTGGGCATCAATCCTGT
reverse GAGTAGTTCACACCAGGCCC
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Heart Overexpression of NHE1 Modulates Extracellular
Matrix Degradation, Transcription Factor Expression,
Metabolism, and Inflammation of Cardiac Tissue
It is known that NHE1 overexpression induces cardiac
hypertrophy. Signaling pathways that mediate this effect have
yet to be understood. Quantitative PCR, immunohistochemical
staining, and Western blot techniques were used to analyze
extracellular matrix (ECM) degradation, transcription factors
expression, metabolism, and inflammation. Figure 2A demon-
strates the modulation of various genes involved in the ECM
degradation in NHE1 transgenic mice. Metalloproteinase in-
hibitor 4 (TIMP4) mRNA expression was significantly reduced
in NHE1 transgenic mice when compared with WT (0.0070 
0.00060 WT vs. 0.0035  0.0004 NHE1; P 	 0.001). Con-
nective tissue growth factor (CTGF) (0.2030  0.0306 WT vs.
0.5978  0.1063 NHE1; P  0.0057) and integrin-3
(0.0005 0.0001 WT vs. 0.0013 0.0003 NHE1; P 0.036)
mRNA expression showed a significant increase in NHE1
group compared with the WT. The mRNA expressions of
collagen3A (Col3A) (0.0901  0.0151 WT vs. 0.0599 
0.0108 NHE1), collagen1 (Col1) (0.0320  0.0049 WT vs.
0.0983  0.0270 NHE1), and matrix metalloproteases 2
(MMP2) (0.0890  0.0073 WT vs. 0.1326  0.0233 NHE1)
show no difference between NHE1 and WT groups.
The mRNA expression of transcription factors cFOS
(0.0026  0.0008 WT vs. 0.0056  0.0012 NHE1), signal
transducer and activator of transcription 3 (STAT3) (0.4624 
0.0810 WT vs. 0.5689  0.1553 NHE1), and cyclic adenosine
monophosphate response element binding protein (CREB)
(0.0050  0.0003 WT vs. 0.0036  0.0008 NHE1) also show
no difference between NHE1 and WT (Fig. 2B). The mRNA
levels of peroxisome proliferator-activated receptor alpha
(PPAR-) and peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1) in active NHE1 group are reduced
compared with WT group, where the reduction is significant for
PPAR- (0.0494 0.0068 WT vs. 0.0273 0.0032 NHE1; P
0.017) and PGC-1 (0.1042 0.0153 WT vs. 0.0532 0.0069
NHE1; P  0.015) as demonstrated in Fig. 2C. Figure 2D
demonstrates that gene expression of interleukin 6 (IL-6) has a
significant increase in NHE1 group when related to WT
(0.0001 2.025 
 105 WT vs. 0.0008 0.0002 NHE1; P 
0.0032). As in agreement with previous data, we have demon-
strated that OPN mRNA expression is strongly increased in
NHE1 group (0.00072  0.00019 WT vs. 0.0016 0.00017
Fig. 2. Cardiac gene modulation in NHE1-overexpressing mice. Quantification of mRNA levels (A, B, C, D, and F) was performed by RT-qPCR in wild-type
mice (WT) and NHE1 transgenic mice (NHE1) normalized to -actin. Results are expressed as the ratio of target gene over -actin  SE. P 	 0.001 vs. WT,
#P 	 0.01 vs. WT, *P 	 0.05 vs. WT. A: quantification of mRNA levels of metalloproteinase inhibitor 4 (TIMP4), connective tissue growth factor (CTGF),
integrin-3 (int3), collagen3A (Col3), collagen1 (Col1), and matrix metalloproteases 2 (MMP2). For TIMP4, integrin-3, collagen3A, collagen1, and MMP2,
n 7 for WT and n 5 for NHE1. For CTGF, n 10 for WT and n 9 for NHE1. B: quantification of mRNA levels of cFos, cyclic adenosine monophosphate
response element binding protein (CREB), signal transducer and activator of transcription 3 (STAT3) (n  7 for WT and n  5 for NHE1). C: quantification
of mRNA levels of peroxisome proliferator-activated receptor alpha (PPAR-) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha
(PGC-1) (n 7 for WT and n 5 for NHE1). D: quantification of mRNA levels of interleukin 6 (IL-6) (n 10 for WT and n 9 for NHE1). E: quantification
of OPN mRNA in WT mice, NHE1 transgenic mice, OPN knockout NHE1 transgenic mice (NHE1·OPN/), and OPN knockout mice (OPN/) normalized
to -actin (n 10 for WT, n 9 for NHE1, n 7 for NHE1·OPN/, n 10 for OPN/). #P	 0.01 vs. WT; ¥P	 0.001 vs. NHE1·OPN/. F: quantification
of mRNA levels of serum and glucocorticoid-regulated kinase 1 (SGK1) (n  7 for WT and n  5 for NHE1). G, H, I: quantification of protein expression in
WT and NHE1 mice was performed by Western blot. Specific protein expression was normalized to -tubulin. Results are expressed as % of WT  SE. #P 	
0.01 vs. WT, *P	 0.05 vs. WT. G, top left: representative Western blot images of connexin 43 protein expression in WT and NHE1. Immunoblotting was against
connexin 43 (43 kDa) and -tubulin (50 kDa). Bottom left: representative immunohistochemistry images of connexin 43 protein expression in WT and NHE1.
Right: quantification of Western blot bands of connexin 43 normalized to -tubulin (n  4 for WT and n  4 for NHE1). H, left: representative Western blot
images of nuclear factor of activated T cells (NFAT) protein expression in WT and NHE1. Immunoblotting was against NFAT (160 kDa) and -tubulin (50 kDa).
Right: quantification of NFAT protein expression normalized to -tubulin (n  9 for WT and n  7 for NHE1). I, left: representative Western blot images of
phosphorylated extracellular signal-regulated kinase (pERK) protein expression in WT and NHE1. Immunoblotting was against pERK (42, 44 kDa) and ERK
(42, 44 kDa). Right: quantification of pERK protein expression normalized to total ERK (n  8 for WT and n  5 for NHE1).
WT
HA
WTNHE1
α-tubulin
NHE1
A B
C D WT NHE1
HA
100 μm100 μm

Fig. 1. Na/H exchanger isoform 1 (NHE1)
mRNA and protein expression in mutated
NHE1-overexpressing mice. A: RT-quantitative
(q)PCR quantification of endogenous NHE1
(eNHE1) mRNA levels in wild-type mice (WT)
and NHE1 transgenic mice (NHE1) normalized
to -actin (n  7 for WT and n  5 for NHE1).
B: RT-qPCR quantification of mutated NHE1
mRNA levels in WT mice and NHE1 trans-
genic mice (NHE1) normalized to -actin (n 
10 for WT and n  9 for NHE1). Results are
expressed as NHE1 mRNA levels  SE *P 	
0.05 vs. WT. C: representative Western blot of
hemagglutinin (HA) tag demonstrating the
comparison of NHE1 protein expression in WT
mice and NHE1 transgenic mice. D: represen-
tative immunohistochemistry images of HA tag
demonstrating the comparison of NHE1 protein
expression in WT mice and NHE1 transgenic
mice.
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NHE1; P 0.0026) (Fig. 2E). As a control we verified that there
is no more OPN expression detected in OPN/ mice.
Furthermore, the mRNA levels of serum and glucocorticoid-
regulated kinase 1 (SGK1) (0.0668  0.0082 WT vs. 0.0416 
0.0043 NHE1; P  0.024), protein expression of connexin 43
(100  11.39% WT vs. 22.82  3.04% NHE1; P  0.023),
and nuclear factor of activated T cells (NFAT) (100  6.84%
WT vs. 47.90  10.08% NHE1; P  0.0014) were also
investigated and found to be significantly reduced in the NHE1
group when compared with control (Fig. 2, F–H). The NHE1
group also showed a significant increase in phosphorylation of
ERK when compared with WT (100  11.97% WT vs.
282.84  50.95% NHE1; P  0.021) (Fig. 2I).
Overexpression of NHE1 in the Heart Increases CD 44
Protein Expression through OPN
Immunohistochemistry images of heart sections demonstrate
that CD 44 was highly expressed in NHE1 transgenic mice
when compared with WT (Fig. 3A). This was further confirmed
by qPCR (CD 44 mRNA: 0.0047  0.0004 WT vs. 0.0096 
0.0010 NHE1; P 	 0.001) (Fig. 3B). Immunostaining and
quantitative PCR results also show that the increase in CD 44
expression in NHE1 transgenic mice was inhibited in OPN
knockout NHE1 transgenic mice (0.0096  0.0010 NHE1 vs.
0.0057  0.0007 NHE1 OPN/; P  0.0073), explaining the
role of OPN in the expression of CD 44. CD 44 mRNA
+
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expression was also significantly reduced in OPN/ mice
when compared with NHE1 overexpressed mice (0.0096 
0.0010 NHE1 vs. 0.0049  0.00074 OPN/; P  0.002).
Heart Overexpression of NHE1 Increases Phosphorylation of
p90 Ribosomal S6 Kinase
Western blot image (Fig. 4A) and its quantification (Fig. 4B)
demonstrate that NHE1 transgenic mice showed increased
phosphorylation of p90RSK (100  10.21% WT vs. 346.95 
82.98% NHE1; P  0.016), the effect of which was signifi-
cantly reduced when OPN was knocked out (346.95  82.98%
NHE1 vs. 82.17  24.18% NHE1 OPN/; P  0.012),
indicating the importance of OPN in phosphorylation of RSK.
Phosphorylation of RSK was also significantly reduced in
OPN/ mice when compared with NHE1-overexpressed mice
(346.95  82.98% NHE1 vs. 134.45  31.54 OPN/; P 
0.03).
OPN Knockout Regressed Collagen Deposition in NHE1-
expressing Transgenic Mice
Cardiac hypertrophic markers including ANP and BNP
mRNA expression, cardiac cross-sectional cell area and colla-
gen deposition were assessed to determine the effect of over-
expression of NHE1 in the heart. Figure 5A depicts an increase
in the whole heart size of NHE1 transgenic mice when com-
pared with the WT. Figure 5B is Masson’s trichrome staining
and Fig. 5E is Picrosirius red staining of collagen, which
showed a significant increase in collagen deposition in the
heart cross sections of NHE1 group (2.9  0.28 WT vs. 9.1 
0.75 NHE1; P	 0.001) and NHE1 OPN/ group (2.9  0.28
WT vs. 6.2  0.19 NHE1 OPN/; P 	 0.001). Figure 5C
shows that there is a significant increase in the ANP (0.6951 
0.18 WT vs. 35.32  5.59 NHE1; P 	 0.001) and BNP
(3.41  0.70 WT vs. 9.19  1.10 NHE1; P 	 0.001) mRNA
expression in the NHE1 transgenic mice. ANP (0.6951  0.18
OPN-/-WT
NHE1 NHE1.OPN-/-
A B
+
€ €
Fig. 3. Role of osteopontin (OPN) in NHE1 overexpression-induced CD44 protein expression. A: representative immunohistochemistry images of CD44
expression in the heart cross sections of wild-type mice (WT), NHE1 transgenic mice (NHE1), OPN knockout NHE1 transgenic mice (NHE1·OPN/), and OPN
knockout mice (OPN/). Bars represent 100 m. B: quantification of mRNA levels of CD 44 normalized to -actin (n  10 for WT, n  9 for NHE1, n 
7 for NHE1·OPN/, n  10 for OPN/). Results are expressed as the ratio of CD44 gene over -actin  SE. P 	 0.001 vs. WT; €P 	 0.01 vs. NHE1.
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Fig. 4. Role of OPN in NHE1 overexpression-induced phosphorylation of p90 ribosomal S6 kinase. A: representative Western blot images of phosphorylated
p90RSK protein expression in wild-type mice (WT), NHE1 transgenic mice (NHE1), OPN knockout NHE1 transgenic mice (NHE1·OPN/), and OPN
knockout mice (OPN/). Immunoblotting was against phospho-p90RSK (90 kDa), RSK2 (80 kDa), and -tubulin (50 kDa). B: quantification of
phospho-p90RSK protein expression normalized to RSK2 (n  7 for WT, n  7 for NHE1, n  3 for NHE1·OPN/, n  6 for OPN/). Results are
expressed as % of WT  SE *P 	 0.05 vs. WT, £P 	 0.05 vs. NHE1.
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WT vs. 30.42  2.84 NHE1 OPN/; P 	 0.001) and BNP
(3.41  0.70 WT vs. 9.45  1.54 NHE1 OPN/; P 
0.0067) mRNA expression also showed significant increase in
NHE1 OPN/ when compared with WT. However, both ANP
(35.32  5.59 NHE1 vs. 0.35 OPN/ ; P 	 0.001) and BNP
(9.19  1.10 NHE1 vs. 2.23  0.32 OPN/; P 	 0.001)
mRNA expression was significantly reduced in OPN/
when compared with NHE1 transgenic mice. Areas of cells of
the internal part of the heart (100  6.59% WT vs. 162.25 
37.01% NHE1; P 0.051) and of the external part of the heart
(100  9.39% WT vs. 169.02  30.75% NHE1; P  0.021)
were measured after WGA staining of heart sections. The
NHE1 group showed a significant increase over WT (Fig. 5D).
The NHE1 OPN/ also showed significant increase in cell
area of internal (100  6.59% WT vs. 147.01  11.64 NHE1
OPN/; P  0.0013) and external (100  9.39% WT vs.
167.92  7.44 NHE1 OPN/; P 	 0.001) parts of the heart
when compared with WT. Moreover, cell areas of internal
(162.25  37.01% NHE1 vs. 84.23  9.35% OPN/; P 
0.026) and external (169.02  30.75% NHE1 vs. 99.35 
15.44% OPN/; P  0.019) parts of the heart also showed
significant reduction in OPN/ mice when compared with
NHE1 transgenic mice. Altogether, our results show that stim-
ulation of NHE1 leads to cardiac hypertrophy, but this increase
was not reversed when OPN was knocked out in the presence
of NHE1 overexpression. However, there was a decrease in
cardiac hypertrophic parameters in OPN/ when compared
with NHE1-overexpressed transgenic mice.
Interestingly, we also show that when NHE1 and NHE1
OPN/ groups were compared, collagen deposition was sig-
nificantly reduced when OPN was knocked out in NHE1
transgenic mice (9.1  0.75 NHE1 vs. 6.2  0.19 NHE1
OPN/; P  0.0031) (Fig. 5E). Moreover, we also show that
collagen deposition was significantly reduced in OPN/ mice
when compared with NHE1 transgenic mice (9.1  0.75
NHE1 vs. 2.3  0.18 OPN/; P 	 0.001).
Heart Overexpression of NHE1 Degrades
Echocardiographic Parameters
To determine the effect of heart overexpression of NHE1 in
transgenic mice over WT mice, echocardiography was per-
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Fig. 5. Role of OPN deficiency and NHE1 overexpression in cardiac morphology. Morphology and histology of heart from wild-type mice (WT), NHE1
transgenic mice (NHE1), OPN knockout NHE1 transgenic mice (NHE1·OPN/), and OPN knockout mice (OPN/). A: representative whole heart images.
B: representative images of Masson’s trichrome staining of heart cross sections. C: quantification of mRNA levels of atrial natriuretic peptide (ANP) and brain
natriuretic peptide (BNP) normalized to -actin (n  10 for WT, n  9 for NHE1, n  7 for NHE1·OPN/, n  10 for OPN/). Results are expressed as
the ratio of target gene over -actin  SE. P 	 0.001 vs. WT, #P 	 0.01 vs. WT, ¥P 	 0.001 vs. NHE1, P 	 0.001 vs. NHE1 OPN/, P 	 0.01 vs.
NHE1 OPN/ D, left representative images of heart cross sections stained with wheat germ agglutinin (WGA). Right: graphical representation of internal and
external cross-sectional heart cell area (n  7 for WT, n  4 for NHE1, n  4 for NHE1·OPN/, n  4 for OPN/ for internal cell area; n  8 for WT,
n  5 for NHE1, n  3 for NHE1·OPN/, n  4 for OPN/ for external cell area). Bars represent 50 m. Results are expressed as % of WT  SE *P 
0.05 vs. WT, #P	 0.01 vs. WT,P	 0.001 vs. WT, P	 0.001 vs. NHE1 OPN/, £P	 0.05 vs. NHE1, P	 0.01 vs. NHE1 OPN/. E, left representative
images of heart cross sections stained with Picrosirius red (PSR). Right: graphical representation of quantification of PSR stain on heart cross sections (n  14
for WT, n  10 for NHE1, n  7 for NHE1·OPN/, n  9 for OPN/). Bars represent 50 m. Results are expressed as relative fibrosis  SE. P 	 0.001
vs. WT, €P 	 0.01 vs. NHE1, ¥P 	 0.001 vs. NHE1, P 	 0.001 vs. NHE1 OPN/.
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formed to measure lengths of interventricular septum in systole
(IVSs), interventricular septum in diastole (IVSd), left ventric-
ular internal diameter in systole (LVIDs), left ventricular
internal diameter in diastole (LVIDd), left ventricular posterior
wall in systole (LVPWs), left ventricular posterior wall in
diastole (LVPWd), ejection fraction (EF), fractional shortening
(FS), and volumes of left ventricle in systole (LVs) and in
diastole (LVd). Figure 6, A and C, respectively, shows that the
LVIDs (2.56  0.09 WT vs. 3.42  0.15 NHE1; P 	 0.001),
LVIDd (3.62  0.08 WT vs. 4.08  0.11 NHE1; P  0.0043),
LVs (24.09  1.95 WT vs. 49.12  5.30 NHE1; P  0.0012),
and LVd (55.70  2.97 WT vs. 74.12  4.94 NHE1; P 
0.0069) were significantly increased for NHE1 group com-
pared with WT. Moreover, EF (56.63  2.79 WT vs. 34.95 
2.69 NHE1; P	 0.001) and FS (29.32  1.96 WT vs. 16.56 
1.40 NHE1; P	 0.001) of ventricle were significantly reduced
in the NHE1 group compared with WT as shown in Fig. 6B.
However, LVIDs remained significantly increased in NHE1
transgenic mouse even when OPN was knocked out (2.56 
0.0854 WT vs. 3.69  0.26 NHE1 OPN/; P 0.0046) (Fig.
6A). Furthermore, EF (56.63  2.79 WT vs. 30.18  4.17;
P 	 0.001) and FS (29.32  1.96 WT vs. 14.18  2.07; P 	
0.001) were significantly reduced in NHE1 OPN/ compared
with WT (Fig. 6B). When we compared the NHE1 group
against OPN/, LVIDs (3.42  0.15 NHE1 vs. 2.31  0.13;
P 	 0.001), LVIDd (4.08  0.11 NHE1 vs. 3.56  0.09
OPN/; P  0.002), LVs (49.12  5.30 NHE1 vs. 19.21 
2.56 OPN/; P 	 0.001), and LVd (74.12  4.94 NHE1 vs.
53.52  3.43 OPN/; P  0.0039) were all significantly
reduced in OPN/ mice. Moreover, EF (34.95  2.69 NHE1
vs. 64.70  3.82 OPN/; P 	 0.001) and FS (16.56  1.40
NHE1 vs. 35.45  3.03 OPN/; P 	 0.001) were signifi-
cantly increased in OPN/ when compared with NHE1 trans-
genic mice.
DISCUSSION
Cardiac hypertrophy is associated with increased expression
of active NHE1 and OPN (10, 43, 44). However, a recent
finding demonstrated that plasma OPN level is significantly
increased in dilated cardiomyopathy subtype rather than hy-
pertrophic cardiomyopathy, indicating that plasma OPN level
is associated with overall heart failure severity (28). Our
previous research had demonstrated that OPN is involved as a
regulator in NHE1-induced cardiac hypertrophy in vitro (22,
23). Moreover, we had previously described that OPN is
increased in cardiomyocytes expressing active NHE1, and this
increase is attributed partly by RSK (23). We hypothesized that
OPN would be a key regulator and a therapeutic target in
NHE1 induced cardiac hypertrophy. To support our hypothe-
sis, we performed experiments on WT mice, NHE1-overex-
pressing transgenic mice, NHE1-overexpressing OPN knock-
out mice, and in OPN knockout mice, to delineate the signaling
mechanisms involved in NHE1-induced cardiac hypertrophy.
Overexpression of Active NHE1 Induces Cardiac
Hypertrophy
We investigated the effects of elevated expression of
active NHE1 on the myocardium of mice. Transgenic mice
expressing active NHE1 showed significant changes in car-
diac hypertrophic parameters including increases in ANP
mRNA expression, increases in cell area, and increased
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Fig. 6. Effect of NHE1 overexpression on heart function.
Graphical representation of echocardiographic parameters of
wild-type mice (WT), NHE1 transgenic mice (NHE1), OPN
knockout NHE1 transgenic mice (NHE1·OPN/), and OPN
knockout mice (OPN/). Results are expressed as raw values
of echocardiographic parameters  SE. P 	 0.001 vs. WT,
#P	 0.01 vs. WT, ¥P	 0.001 vs. NHE1, P	 0.01 vs. NHE1
OPN/, €P 	 0.01 vs. NHE1, P 	 0.001 vs. NHE1
OPN/. A: graphical representation of the lengths of interven-
tricular septum in systole (IVSs), interventricular septum in
diastole (IVSd), left ventricular internal diameter in systole
(LVIDs), left ventricular internal diameter in diastole (LVIDd),
left ventricular posterior wall in systole (LVPWs), and left
ventricular posterior wall in diastole (LVPWd) (n 10 for WT,
n  9 for NHE1, n  7 for NHE1·OPN/, n  10 for
OPN/). B: graphical representation of ejection fraction (EF)
and fractional shortening (FS) (n  10 for WT, n  9 for
NHE1, n  7 for NHE1·OPN/, n  10 for OPN/). C:
graphical representation of volumes of left ventricle in systole
(LVs) and diastole (LVd) (n  10 for WT, n  9 for NHE1,
n  7 for NHE1·OPN/, n  10 for OPN/).
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interstitial fibrosis (Fig. 5), which are in accordance with
previous reports (24, 44).
Elevated expression and activity of NHE1 also result in
cardiac remodeling by regulating matrix metalloproteases
(MMPs) and tissue inhibitor of metalloproteases (TIMPs) (44).
We observed that expression of TIMP4 was significantly re-
duced in NHE1-overexpressed transgenic mice, which is in
agreement with a previous study that reported decreased
TIMP4 in compensatory heart (9). Our results show that
PPAR and PGC1 were found to be downregulated in NHE1-
overexpressed transgenic mice (Fig. 2C), which is in agree-
ment with a previous study performed on failing hearts from
patients with dilated cardiomyopathies (30). A previous study
demonstrated the role of SGK1 in NHE expression and activ-
ity, as well as its involvement in contributing various indices of
cardiac hypertrophy including ANP mRNA expression, colla-
gen deposition, and decreased EF finally leading to cardiac
remodeling and heart failure (39). Moreover, it has been
reported that SGK1 is involved in inflammatory, fibrotic, and
oxidative pathways leading to cardiac hypertrophy (19). In
contrast, our results demonstrate that NHE1-overexpressed
transgenic mice showed a decreased expression of SGK1 (Fig.
2F). Previous research indicated that IL-6 mediates cardiac
remodeling and cardiac hypertrophy (8, 21, 27), which is in
accordance with our study, which showed an upregulation of
IL-6 in NHE1-overexpressed transgenic mice (Fig. 2D). We
show a decrease in connexin 43 protein in NHE1-overex-
pressed transgenic mice (Fig. 2G), in agreement with a previ-
ous study that showed decrease in connexin 43 in the presence
of high mechanical load leading to hypertrophied myocardium
(3). Furthermore, it was reported that NHE1 negatively regu-
lates connexin 43 expression in phenylephrine-induced cardiac
hypertrophy (32). Overall, these findings suggest that active
NHE1 is sufficient to induce cardiac hypertrophy.
OPN Mediates NHE1-induced Cardiac Hypertrophy
through p90 RSK
A previous study also reported that expression of active
NHE1 upregulated OPN gene expression significantly (44).
Our study confirms that overexpression of NHE1 in the heart
upregulated cardiac mRNA expression of OPN, indicating the
importance of active NHE1 in expression of OPN. It was
previously reported that OPN is a ligand for receptor CD44
(14, 31). Cell adhesion, cell survival, and gene expression were
modulated by integrin and CD44-mediated pathways signaled
by OPN (7). OPN is susceptible to cleavage at integrin binding
motifs (4). Moreover, our results show an increased upregula-
tion of CD44 mRNA and protein expression in transgenic mice
overexpressing NHE1, which was reduced when OPN was
knocked out in NHE1 transgenic mice (Fig. 3). We are the first
to report these findings. Together these findings confirm the
correlation that OPN expression is upregulated in heart over-
expressing NHE1. Moreover, our previous in vitro study on
cardiomyocytes showed that NHE1-induced OPN expression
facilitated cardiac hypertrophy as demonstrated by the increase
in ANP mRNA expression, cell surface area, and protein
content. These markers of hypertrophy were reversed when
OPN was downregulated by transfection of siRNA directed
against OPN in cardiomyocytes expressing active NHE1 (23).
In contrast, in our present in vivo study the increase in ANP
mRNA expression and cell surface area in NHE1 transgenic
mice was not reversed when OPN was knocked out (Fig. 5C).
The discrepancy observed with our in vitro (23) findings vs.
our in vivo findings may be due to the study model with the
former study being carried out in an in vitro cell line, whereas
the current study was carried out in an in vivo model. The
decrease in cell area and ANP mRNA expression observed in
the in vitro model may have been compensated for by external
factors in the in vivo model.
Previous reports revealed the involvement of ERK and p90
RSK in mediating cardiac hypertrophy (37). It was also re-
ported that ERK is mediating activation of NHE1 (2, 18). Our
results showed increased phosphorylated ERK in overex-
pressed NHE1 transgenic mice (Fig. 2I). Moreover, previous
studies reported that RSK is considered to enhance NHE1
activity (34, 36), which is in accordance with our results where
active NHE1 transgenic mice showed increased phosphoryla-
tion of RSK (Fig. 4). Our novel findings also show that the
phosphorylation of RSK was regressed in NHE1 OPN/ mice
(Fig. 4), suggesting that the OPN is a key regulator in the
activation of RSK. Furthermore, increased fibrosis in overex-
pressed NHE1 transgenic mice, which was reduced in NHE1
OPN/ mice (Fig. 5E), also explains the role of OPN in
NHE1-induced cardiac hypertrophy.
However, our study also found out that cardiac hypertrophy
induced by NHE1 was not reversed when OPN was knocked
out in NHE1 transgenic mice, demonstrated in ANP, BNP
mRNA expressions and cardiac cell area of NHE1 OPN/.
Moreover, heart function measured by echocardiography was
also not improved in NHE1 OPN/ mice. Furthermore, a
significant but not complete reduction in relative fibrosis was
observed in NHE1 OPN/. The partial reduction in cardiac
fibrosis may be attributed to the fact that fibrosis may also be
caused by other factors including TGF- (17, 38), accounting
for the inability of knocking out OPN for a complete reduction
of fibrosis. Together our findings suggest that knocking out
OPN only helps in a partial reduction of NHE1-induced cardiac
hypertrophy.
Our study also shows no significant changes for cardiac
hypertrophic parameters when WT is compared with OPN/
mice. However, when OPN/ was compared with NHE1
transgenic mice, we found that the parameters were signifi-
cantly reduced vs. OPN/, which could be attributed to the
fact that there is no change between WT and OPN/. This
suggests that OPN/ mice are similar to WT mice, and
OPN/ mice need stimuli like angiotensin, myocardial infarc-
tion, or NHE1 overexpression to produce cardiac hypertrophic
effects (20).
In conclusion, our findings demonstrate that overexpression
of NHE1 results in upregulation of OPN, which ultimately
leads to cardiac hypertrophy mediated through CD44 and p90
ribosomal s6 kinase expression.
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